CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.
Follow CRSP
CRISPR Therapeutics AG (CRSP) Altman Z-score
CRISPR Therapeutics AG's Altman Z-score for fiscal 2025 is 7.04, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 7.04 | 1.15 |
| FY2024 | 5.89 | (2.86) |
| FY2023 | 8.76 | 4.19 |
| FY2022 | 4.57 | (6.91) |
| FY2021 | 11.48 | (25.51) |
| FY2020 | 36.99 | 20.21 |
| FY2019 | 16.78 | 9.11 |
| FY2018 | 7.67 | 1.16 |
| FY2017 | 6.51 | 5.01 |
| FY2016 | 1.50 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.81 | — | 0.97 | |
| Retained earnings / total assets | (0.86) | — | −1.20 | |
| EBIT / total assets | (0.29) | — | −0.97 | |
| Market value of equity / total liabilities | 13.73 | — | 8.24 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Safe zone | 7.04 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 6.42 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CRSP CRISPR Therapeutics AG | 7.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 4.4× |
| COGT Cogent Biosciences, Inc. compare | 3.5× |
| PTCT PTC Therapeutics, Inc. compare | 1.9× |
| TVTX Travere Therapeutics, Inc. compare | 1.8× |
| SRRK Scholar Rock Holding Corporation compare | 1.1× |
| ORKA Oruka Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets